Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dermatrends develops ground-breaking NSAID
The Dermatrends’ nonsteroidal anti-inflammatory drug (NSAID) patch has been tested extensively in vitro, indicating that drugs such as meloxicam can be delivered to match systemic blood level concentrations
The Dermatrends’ nonsteroidal anti-inflammatory drug (NSAID) patch has been tested extensively in vitro, indicating that drugs such as meloxicam can be delivered to match systemic blood level concentrations
PTC124 represents a first-in-class, orally delivered investigational new drug in development for the treatment of genetic disorders due to nonsense mutations. Nonsense mutations are single-point alterations in the
The approximate $19.7 million acquisition price was financed through non-dilutive, asset-based funding provided by Westernbank Business Credit Division of Westernbank Puerto Rico. The operations in Manati, Puerto Rico
In taking a public stand against the military’s investigational anthrax vaccine, the band makes it possible to reach huge numbers of the general public to inform them about
HuC242-DM4, ImmunoGen’s tumor-activated prodrug (TAP) compound, is in development for the treatment of CanAg-expressing cancers, such as gastrointestinal and non-small cell lung cancers. ImmunoGen’s TAP technology uses tumor-targeting
Mycamine (micafungin sodium), an antifungal in the echinocandin class, was approved by the FDA on March 16, 2005 for the treatment of patients with esophageal candidiasis and for
Under the agreement, Serono has licensed worldwide exclusive rights to Syntonix’ Transceptor and Synfusion technologies for the development and commercialization of interferon-beta:Fc products. Syntonix’ technologies may enable the
Following its initial review of a supplemental new drug application for Lexapro (excitalopram oxalate) in social anxiety disorder, the FDA has determined the application not approvable and has
The study is designed to evaluate the safety and immunogenicity of Fluviral in healthy adults and has been expanded from 300 to 1,000 subjects. It is intended to
“A key aspect of anthrax spore biology concerns the germination process through which the dormant spore becomes a reproductive, disease-causing bacterium,” explained Al Claiborne, the study’s principal investigator.